Welcome to our dedicated page for Neuroone Med Technologies news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on Neuroone Med Technologies stock.
NeuroOne Medical Technologies Corp (NMTC) develops cutting-edge thin film electrode solutions for neurological diagnostics and treatment. This page provides centralized access to official company news, including product advancements, regulatory milestones, and strategic developments in the neuromodulation sector.
Investors and healthcare professionals will find timely updates on NMTC's innovations in continuous EEG monitoring, brain stimulation technologies, and minimally invasive therapeutic devices. The curated news collection offers insights into how the company addresses complex neurological disorders like epilepsy and Parkinson's disease.
Key updates include FDA clearances, research partnerships with medical institutions, and advancements in electrode technology for precise neurodiagnostics. All content is sourced from verified releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page to stay informed about NMTC's contributions to medical technology and its evolving role in improving neurological care. Check regularly for objective updates on developments impacting the neuromodulation industry and patient treatment paradigms.
NeuroOne Medical Technologies (NMTC) has announced the pricing of an underwritten public offering of 16,000,000 shares of common stock at $0.50 per share, aiming to raise $8.0 million in gross proceeds.
The company has granted the underwriter, Ladenburg Thalmann & Co. Inc., a 45-day option to purchase up to an additional 2,400,000 shares at the public offering price less underwriting discount. The offering is expected to close around April 7, 2025.
The net proceeds will be used for general working capital purposes. The shares will be issued under a shelf registration statement on Form S-3 that was declared effective by the SEC on August 16, 2024.
NeuroOne Medical Technologies (NMTC), a medical technology company focused on neurological disorder surgical care, has announced a proposed underwritten registered public offering of common stock shares. The company plans to grant the underwriter a 45-day option to purchase up to an additional 15% of the offered shares.
Ladenburg Thalmann & Co. Inc. will serve as the sole book-running manager for this offering, which will be conducted under an effective shelf registration statement on Form S-3. The offering's completion, size, and terms are subject to market conditions, with no guarantees of successful execution.
The shares will be available through a preliminary prospectus supplement and accompanying prospectus to be filed with the SEC. The offering will only proceed in jurisdictions where it complies with securities laws and registration requirements.
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa appeared on Today's Marketplace alongside Dr. Jessica Clark to discuss advancements in epilepsy treatment and the company's OneRF® Ablation System. The system, which is the first and only FDA 510(k)-cleared device of its kind, combines the ability to record brain activity and perform RF ablation using a single device.
The OneRF® system consists of three main components: an electrode for stimulation, recording, and ablation; a temperature probe; and a radio frequency heat generator system. This innovation addresses a significant medical need, as over 50 million people worldwide suffer from epilepsy, with approximately one-third of patients experiencing medication-resistant seizures.
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa appeared on Today's Marketplace to discuss epilepsy treatment innovations alongside Dr. Jessica Clark from Creighton University. The discussion centered on the company's OneRF® Ablation System, which is the first and only FDA 510(k)-cleared device that can both record brain activity and perform RF ablation using the same device.
The system consists of three main components: an electrode for stimulation, recording, and monitoring brain activity with ablation capability, a temperature probe, and a radio frequency heat generator system. This innovation addresses a critical need, as over 50 million people worldwide suffer from epilepsy, with approximately one-third of patients experiencing medication-resistant seizures.
NeuroOne Medical Technologies (Nasdaq: NMTC) has accelerated its FDA 510(k) submission timeline for the OneRF® Trigeminal Nerve Ablation System to May 2025, approximately two months ahead of the original schedule. The system aims to treat facial pain caused by trigeminal neuralgia through minimally invasive radiofrequency ablation.
This represents the company's second radiofrequency ablation technology utilizing their patented OneRF® Technology Platform. According to Research and Markets, the trigeminal neuralgia therapeutics market is projected to grow from $262 million in 2024 to $416 million by 2030, driven by an aging population.
If FDA cleared, NeuroOne anticipates potential revenue generation from trigeminal nerve ablation in late 2025, which wasn't previously expected within the 2025 calendar year. This would add to their portfolio of three FDA-cleared product families.
NeuroOne Medical Technologies (NASDAQ: NMTC), a medical technology company specializing in neurological disorder surgical care solutions, has announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference.
CEO Dave Rosa will deliver a virtual corporate presentation on Wednesday, March 19, 2025, at 9:20 a.m. eastern time. Following the presentation, one-on-one meetings will be available through Oppenheimer. Interested parties can access the live webcast or replay through the provided link or NeuroOne's investor relations website events page.
NeuroOne Medical Technologies (NMTC) reported strong Q1 FY2025 results with total revenue of $6.3M, including $3.3M in product revenue (235% increase YoY) and a $3.0M upfront license payment from Zimmer Biomet. Product gross margin improved to 58.9% from 27.2% year-over-year, while operating expenses decreased 12% to $3.2M.
The company reported net income of $1.8M ($0.06 per share) compared to a net loss of $3.3M in Q1 FY2024. NeuroOne reaffirmed its FY2025 guidance, projecting product revenue between $8.0-10.0M (132-190% growth) and gross margins of 47-51%. The OneRF Ablation System has been placed in 5 prominent epilepsy centers, with positive patient outcomes reported.
The company remains debt-free with $1.1M in cash and $4.1M in working capital as of December 31, 2024. NeuroOne also regained compliance with Nasdaq's minimum share price requirements.
NeuroOne Medical Technologies (NASDAQ: NMTC), a medical technology company specializing in neurological disorder surgical care, has announced its upcoming fiscal first quarter 2025 financial results release scheduled for February 12, 2025, before market open.
The company will host an investor conference call and webcast at 8:30 a.m. Eastern time on the same day, featuring management's discussion of Q1 2025 results, a corporate update, and a Q&A session. The earnings call will be accessible via U.S. toll-free (888-506-0062) and international (973-528-0011) dial-in numbers, with participant access code 234314.
A playback will be available until February 26, 2025, through domestic and international replay numbers, using passcode 51728. The webcast replay will be accessible through February 13, 2025.
NeuroOne Medical Technologies (Nasdaq: NMTC) has regained compliance with Nasdaq Capital Market's continued listing requirements for minimum share price under Rule 5550(a)(2). The company received confirmation from Nasdaq's Listings Qualifications Hearing Department on February 3, 2025, resulting in the cancellation of a previously scheduled hearing.
The company also reported preliminary unaudited first quarter fiscal 2025 total revenue of $6.2 million, comprising $3.2 million in product revenue and a one-time $3.0 million license revenue payment. NeuroOne's CEO Dave Rosa highlighted the company's focus on their OneRF Ablation System, which is the first and only FDA-cleared device for RF ablation in the brain. The company will provide further updates during their upcoming earnings call scheduled for February 12, 2025, at 8:30 am eastern time.
NeuroOne Medical Technologies (NASDAQ: NMTC) announced preliminary unaudited revenue for Q1 fiscal 2025 (ended December 31, 2024) of $6.2 million, a significant increase from $1.0 million in Q1 fiscal 2024. This includes a one-time $3.0 million collaboration payment from Zimmer Biomet for the OneRF™ Ablation System commercialization agreement, plus $3.2 million in product revenue, representing a 227% increase year-over-year.
The company reiterated its fiscal 2025 product revenue guidance (excluding collaboration revenue) of $8.0-$10.0 million, with expected product gross margins between 47-51%. The Zimmer Biomet agreement includes potential additional milestone payments based on performance criteria. Complete financial results for the quarter are expected in February 2025.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
